- Home
- BIIB
BIIB
Biogen Inc.
as 12-03-2024 11:33am EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 25.1B | IPO Year: | 1991 |
| Target Price: | $258.57 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.06 | EPS Growth: | 10.05 |
| 52 Week Low/High: | $153.62 - $268.30 | Next Earning Date: | 10-30-2024 |
| Revenue: | $9,607,500,000 | Revenue Growth: | -3.86% |
| Revenue Growth (this year): | -0.03% | Revenue Growth (next year): | -1.33% |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
Morningstar Research
a day ago
Analyst Report: Biogen Inc.
MT Newswires
4 days ago
Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea
Zacks
4 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Insider Monkey
5 days ago
Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?
PR Newswire
6 days ago
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Insider Monkey
6 days ago
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?
Investor's Business Daily
7 days ago
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?
Insider Monkey
11 days ago
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.